Cytosorbents (CTSO) Expected to Announce Earnings on Monday

Cytosorbents (NASDAQ:CTSO) will likely be issuing its Q4 2025 results after the market closes on Monday, March 30th. Analysts expect the company to announce earnings of ($0.06) per share and revenue of $9.2150 million for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Wednesday, March 25, 2026 at 4:30 PM ET.

Cytosorbents Trading Up 3.4%

Cytosorbents stock opened at $0.66 on Monday. Cytosorbents has a 12 month low of $0.60 and a 12 month high of $1.39. The company has a market capitalization of $41.45 million, a price-to-earnings ratio of -3.67 and a beta of 1.36. The business’s fifty day simple moving average is $0.69 and its two-hundred day simple moving average is $0.76. The company has a current ratio of 2.11, a quick ratio of 1.71 and a debt-to-equity ratio of 1.61.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of CTSO. Goldman Sachs Group Inc. boosted its position in shares of Cytosorbents by 149.2% during the first quarter. Goldman Sachs Group Inc. now owns 62,662 shares of the medical research company’s stock valued at $63,000 after buying an additional 37,519 shares during the last quarter. Vanguard Group Inc. raised its position in Cytosorbents by 3.7% in the 3rd quarter. Vanguard Group Inc. now owns 2,204,294 shares of the medical research company’s stock worth $2,059,000 after buying an additional 79,535 shares during the last quarter. Citadel Advisors LLC lifted its stake in Cytosorbents by 127.3% during the 3rd quarter. Citadel Advisors LLC now owns 65,690 shares of the medical research company’s stock valued at $61,000 after acquiring an additional 36,790 shares during the period. CIBC Bancorp USA Inc. purchased a new stake in shares of Cytosorbents during the 3rd quarter valued at about $161,000. Finally, Avenir Corp boosted its holdings in shares of Cytosorbents by 2.9% during the 4th quarter. Avenir Corp now owns 5,230,099 shares of the medical research company’s stock valued at $3,343,000 after acquiring an additional 147,261 shares during the last quarter. Hedge funds and other institutional investors own 32.87% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on CTSO shares. D. Boral Capital reiterated a “buy” rating and issued a $10.00 price target on shares of Cytosorbents in a research note on Monday, January 12th. Weiss Ratings restated a “sell (e+)” rating on shares of Cytosorbents in a research note on Friday, January 9th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Cytosorbents presently has a consensus rating of “Hold” and a consensus target price of $5.38.

About Cytosorbents

Cytosorbents Corporation, founded in 2011 and headquartered in Princeton, New Jersey, is a medical device company focused on critical care and extracorporeal blood purification. The company’s flagship product, CytoSorb, is a hemoadsorption cartridge designed to remove excessive inflammatory mediators such as cytokines, bilirubin and myoglobin from a patient’s blood. By targeting the molecular drivers of hyperinflammation, CytoSorb is intended to stabilize patients undergoing septic shock, cardiac surgery, trauma and organ failure.

CytoSorb has secured regulatory clearance in Europe (CE mark) and is available in more than 65 countries, with a growing presence in Asia, the Middle East and Latin America.